Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTESBNC)

• DTT Name: M-phase inducer phosphatase 3 (MPIP3)
• Synonyms: Dual specificity phosphatase Cdc25C; Cdc25C phosphatase
• Gene Name: CDC25C
• DTT Type: Literature-reported target; [1]
• BioChemical Class: Phosphoric monoester hydrolase
• UniProt ID: MPIP3_HUMAN
• TTD ID: T19011
• EC Number: EC 3.1.3.48
• Sequence:
  MSTELFSSTREEGSSGSGPSFRSNQRKMLNLLLERDTSFTVCPDVPRTPVGKFLGDSANL
  SILSGGTPKRCLDLSNLSSGEITATQLTTSADLDETGHLDSSGLQEVHLAGMNHDQHLMK
  CSPAQLLCSTPNGLDRGHRKRDAMCSSSANKENDNGNLVDSEMKYLGSPITTVPKLDKNP
  NLGEDQAEEISDELMEFSLKDQEAKVSRSGLYRSPSMPENLNRPRLKQVEKFKDNTIPDK
  VKKKYFSGQGKLRKGLCLKKTVSLCDITITQMLEEDSNQGHLIGDFSKVCALPTVSGKHQ
  DLKYVNPETVAALLSGKFQGLIEKFYVIDCRYPYEYLGGHIQGALNLYSQEELFNFFLKK
  PIVPLDTQKRIIIVFHCEFSSERGPRMCRCLREEDRSLNQYPALYYPELYILKGGYRDFF
  PEYMELCEPQSYCPMHHQDHKTELLRCRSQSKVQEGERQLREQIALLVKDMSP
• Function: Tyrosine protein phosphatase required for progression of the cell cycle. When phosphorylated, highly effective in activating G2 cells into prophase. Directly dephosphorylates CDK1 and activates its kinase activity. Functions as a dosage-dependent inducer in mitotic control.
• KEGG Pathway:
  Cell cycle (hsa04110)
  Oocyte meiosis (hsa04114)
  Progesterone-mediated oocyte maturation (hsa04914)
  MicroRNAs in cancer (hsa05206)
• Reactome Pathway:
  Cyclin B2 mediated events (R-HSA-157881)
  Activation of ATR in response to replication stress (R-HSA-176187)
  RHO GTPases activate PKNs (R-HSA-5625740)
  Cyclin A/B1 associated events during G2/M transition (R-HSA-69273)
  Chk1/Chk2(Cds1) mediated inactivation of Cyclin B (R-HSA-75035)
  Polo-like kinase mediated events (R-HSA-156711)

Molecular Interaction Atlas (MIA) of This DTT

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MX-7065	DMP26BW	Solid tumour/cancer	2A00-2F9Z	Terminated	[1]

3 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BN-82002	DMXY574	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
BN-82685	DMZME4N	Discovery agent	N.A.	Investigative	[3]
NSC-663284	DMEXW31	Discovery agent	N.A.	Investigative	[3]

References

• [1] Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11).
• [2] Synthesis of small molecule CDC25 phosphatases inhibitors. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5809-12.
• [3] Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C. Bioorg Med Chem Lett. 2006 Jan 1;16(1):171-5.